BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lin C, Kao J. Review article: the prevention of hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2018;48:5-14. [DOI: 10.1111/apt.14683] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Tang S, Wu W, Wan H, Wu X, Chen H. Knockdown of NHP2 inhibits hepatitis B virus X protein-induced hepatocarcinogenesis via repressing TERT expression and disrupting the stability of telomerase complex. Aging (Albany NY) 2020;12:19365-74. [PMID: 33044946 DOI: 10.18632/aging.103810] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex (Engl Ed) 2021;86:403-32. [PMID: 34483073 DOI: 10.1016/j.rgmxen.2021.04.002] [Reference Citation Analysis]
3 Zhang X, Yin S, Ma K. Bioinformatics analysis of different candidate genes involved in hepatocellular carcinoma induced by HepG2 cells or tumor cells of patients. J Int Med Res 2020;48:300060520932112. [PMID: 32567431 DOI: 10.1177/0300060520932112] [Reference Citation Analysis]
4 Choi GH, Kim G, Choi J, Han S, Lim Y. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation. Aliment Pharmacol Ther 2019;50:215-26. [DOI: 10.1111/apt.15311] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 7.7] [Reference Citation Analysis]
5 Flores JE, Thompson AJ, Ryan M, Howell J. The Global Impact of Hepatitis B Vaccination on Hepatocellular Carcinoma. Vaccines 2022;10:793. [DOI: 10.3390/vaccines10050793] [Reference Citation Analysis]
6 Tsushima K, Tsuge M, Hiraga N, Uchida T, Murakami E, Makokha GN, Kurihara M, Nomura M, Hiyama Y, Fujino H, Ono A, Nakahara T, Yamauchi M, Abe-Chayama H, Kawaoka T, Miki D, Imamura M, Aikata H, Hayes CN, Chayama K. Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice. J Gastroenterol 2019;54:650-9. [PMID: 30790056 DOI: 10.1007/s00535-019-01558-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Zhang X, Guan L, Tian H, Zeng Z, Chen J, Huang D, Sun J, Guo J, Cui H, Li Y. Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma. Front Oncol 2021;11:686962. [PMID: 34568017 DOI: 10.3389/fonc.2021.686962] [Reference Citation Analysis]
8 Lin X, Song A, Lu J, Zheng S, Hu Z, Ma L, Cao Z, Li H, Zheng Y, Ren S, Chen X. Study on the Retreatment, Outcome, and Potential Predictors of Recurrence in Patients With Recurrence of Hepatitis B After Functional Cure. Front Immunol 2022;13:879835. [DOI: 10.3389/fimmu.2022.879835] [Reference Citation Analysis]
9 Jang TY, Wei YJ, Liu TW, Yeh ML, Liu SF, Hsu CT, Hsu PY, Lin YH, Liang PC, Hsieh MH, Ko YM, Tsai YS, Chen KY, Lin CC, Tsai PC, Wang SC, Huang CI, Lin ZY, Chen SC, Chuang WL, Huang JF, Dai CY, Huang CF, Yu ML. Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. Sci Rep 2021;11:8184. [PMID: 33854160 DOI: 10.1038/s41598-021-87679-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Zhu GQ, Wang K, Wang B, Zhou YJ, Yang Y, Chen EB, Zhou ZJ, Zhou SL, Shi YH, Zhou J, Dai Z. Aspartate aminotransferase-to-platelet ratio index predicts prognosis of hepatocellular carcinoma after postoperative adjuvant transarterial chemoembolization. Cancer Manag Res 2019;11:63-79. [PMID: 30588111 DOI: 10.2147/CMAR.S186150] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
11 Hasegawa K, Nishikawa H, Enomoto H, Iwata Y, Sakai Y, Ikeda N, Takashima T, Aizawa N, Takata R, Yoh K, Ishii N, Yuri Y, Nishimura T, Iijima H, Hatano E, Fujimoto J, Nishiguchi S. Proposed model for the prediction of intrahepatic covalently closed circular DNA level in patients with chronic hepatitis B. Hepatol Res 2018;49:271-83. [DOI: 10.1111/hepr.13280] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
12 Lin CL, Kao JH. Hepatitis B: Immunization and Impact on Natural History and Cancer Incidence. Gastroenterol Clin North Am. 2020;49:201-214. [PMID: 32389359 DOI: 10.1016/j.gtc.2020.01.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
13 Thi EP, Dhillon AP, Ardzinski A, Bidirici-Ertekin L, Cobarrubias KD, Cuconati A, Kondratowicz AS, Kwak K, Li AHL, Miller A, Pasetka C, Pei L, Phelps JR, Snead NM, Wang X, Ye X, Sofia MJ, Lee ACH. ARB-1740, a RNA Interference Therapeutic for Chronic Hepatitis B Infection. ACS Infect Dis 2019;5:725-37. [PMID: 30403127 DOI: 10.1021/acsinfecdis.8b00191] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
14 Lin CL, Tseng KC, Chen KY, Liao LY, Kao JH. Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy. J Formos Med Assoc 2020;119:1483-9. [PMID: 32653388 DOI: 10.1016/j.jfma.2020.07.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Sun X, Wang C, Wang B, Yang X, Xu H, Shen M, Zhu K. Efficacy of Nucleotide/Nucleoside Analogues and Hepatitis B Immunoglobulin Therapy in Blocking Mother-to-Child Transmission of Hepatitis B in an Eastern Chinese Group. Infect Dis Obstet Gynecol 2020;2020:4305950. [PMID: 33380780 DOI: 10.1155/2020/4305950] [Reference Citation Analysis]
16 Harputluoglu M, Carr BI. Hepatitis B Before and After Hepatocellular Carcinoma. J Gastrointest Cancer 2021. [PMID: 34762265 DOI: 10.1007/s12029-021-00745-4] [Reference Citation Analysis]
17 Moyad MA. Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part III. Curr Urol Rep 2020;21:22. [PMID: 32367257 DOI: 10.1007/s11934-020-00972-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Xue C, Wang K, Jiang X, Gu C, Yu G, Zhong Y, Liu S, Nie Y, Zhou Y, Yang H. The Down-Regulation of SUZ12 Accelerates the Migration and Invasion of Liver Cancer Cells via Activating ERK1/2 Pathway. J Cancer 2019;10:1375-84. [PMID: 31031847 DOI: 10.7150/jca.29932] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
19 Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022;399:61-116. [PMID: 34863359 DOI: 10.1016/S0140-6736(21)01701-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 30.0] [Reference Citation Analysis]
20 Su T, Liu C, Tseng T, Chou S, Liu C, Yang H, Wu S, Chen P, Chen D, Chen C, Kao J. Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma. Aliment Pharmacol Ther 2019;49:589-98. [DOI: 10.1111/apt.15132] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
21 Song A, Lin X, Chen X. Functional cure for chronic hepatitis B: accessibility, durability, and prognosis. Virol J 2021;18:114. [PMID: 34082765 DOI: 10.1186/s12985-021-01589-x] [Reference Citation Analysis]
22 Xia Y, Liang TJ. Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of Hepatitis B Virus Infection. Gastroenterology 2019;156:311-24. [PMID: 30243618 DOI: 10.1053/j.gastro.2018.07.057] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
23 Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex 2021:S0375-0906(21)00061-6. [PMID: 34384668 DOI: 10.1016/j.rgmx.2021.04.002] [Reference Citation Analysis]
24 Kao J. Hepatitis B: From control to cure. Journal of the Formosan Medical Association 2018;117:868-70. [DOI: 10.1016/j.jfma.2018.08.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
25 Leone V, Ali A, Weber A, Tschaharganeh DF, Heikenwalder M. Liver Inflammation and Hepatobiliary Cancers. Trends Cancer 2021;7:606-23. [PMID: 33674229 DOI: 10.1016/j.trecan.2021.01.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Zamor PJ, Lane AM. Interpretation of HBV Serologies. Clin Liver Dis 2021;25:689-709. [PMID: 34593148 DOI: 10.1016/j.cld.2021.06.012] [Reference Citation Analysis]
27 Lim J, Chon YE, Kim MN, Lee JH, Hwang SG, Lee HC, Ha Y. Cirrhosis, Age, and Liver Stiffness-Based Models Predict Hepatocellular Carcinoma in Asian Patients with Chronic Hepatitis B. Cancers (Basel) 2021;13:5609. [PMID: 34830764 DOI: 10.3390/cancers13225609] [Reference Citation Analysis]
28 Liang LY, Wong VW, Tse YK, Yip TC, Lui GC, Chan HL, Wong GL. Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2019;49:1509-1517. [PMID: 31025388 DOI: 10.1111/apt.15269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
29 Kazmi SA, Rauf A, Shafique F, Asim N, Shafi N, Hassan MU. Kashmiri refugees at the verge of hepatitis B and C epidemic in the State of Azad Jammu and Kashmir, Pakistan. Rev Saude Publica 2022;56:33. [PMID: 35544886 DOI: 10.11606/s1518-8787.2022056003479] [Reference Citation Analysis]
30 Hsu YC, Tseng CH, Huang YT, Yang HI. Application of Risk Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: Current Status and Future Perspective. Semin Liver Dis 2021;41:285-97. [PMID: 34161993 DOI: 10.1055/s-0041-1730924] [Reference Citation Analysis]